



Science For A Better Life



Investor Conference Call

Q3 2007 Results

Werner Wenning, CEO

November 6 | 2007

Disclaimer



This presentation contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in our public reports filed with the Frankfurt Stock Exchange and with the U.S. Securities and Exchange Commission (including our Form 20-F). The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.



Q3 – Bayer Continues on a Successful Path

- Delivering growth and performance
- Further strategic progress
- Integration of Schering progressing well
- Strong cash performance and reduction of net debt
- Optimistic about future developments

Q3 2007 Investor Conference Call • Werner Wenning • Page 3

Q3'2007 – Upward Trend Unabated




Key Figures

Underlying EBITDA by Subgroup

In € million, Δ% y-o-y

	Sales 7,793	EBITDA* 1,559	EBIT* 953	Core EPS €0.81
Δ%	+ 4%	+ 7%	+ 24%	+ 5%
Δ% Adj. **	+ 7%			




* Before special items


** Currency & portfolio adjusted

Q3 2007 Investor Conference Call • Werner Wenning • Page 4

HealthCare – Business Momentum Gained



CropScience – Strong Business Expansion




MaterialScience – Margins up on Higher Prices



Q3'07 Sales

In € million, Δ% y-o-y



MaterialScience €2,625m; +1% (+4%)


() Currency & portfolio adjusted

Q3 2007 Investor Conference Call • Werner Wenning • Page 7

Earnings

Underlying EBITDA

Underlying EBIT



Strong Working Capital Performance, Lower Net Debt




Q3'07 Cash Flow

In € million

	GCF	NCF cont.	Investments	oFCF
	1,165	1,623	482	1,141
Δ % y-o-y	+3%	+7%	+48%	-4%

Net Debt Development

In € billion



Q3 2007 Investor Conference Call • Werner Wenning • Page 8

Expected News Flow



Timing	Milestone
Nov	■ ASH abstracts online
Dec, 8-11	■ ASH presentations, conference call, more visibility on longer-term safety
Nov/Dec	■ Initiation of Phase-III clinical trials in medical ill (Xarelto)
Nov/Dec	■ Approval of Nexavar for HCC in the US
Feb, 26	■ Dividend proposal
Feb, 28	■ Publication of Q4 statements

Q3 2007 Investor Conference Call • Werner Wenning • Page 9

Positive Outlook: 2007 to Set a New Record



Group	Subgroups
<ul style="list-style-type: none"> ■ Sales above €32 bn (approx. 6 percent growth portfolio and currency adjusted) ■ Margin increase by at least one percentage point over last year's 19.3% 	<ul style="list-style-type: none"> ■ HealthCare (raised) Growth in all divisions at or above market. Margin* above 25%. ■ CropScience (reiterated) Sales above previous year's 2nd half. Margin* above 22%. ■ MaterialScience (up-dated) Higher volumes and good, value-creating earnings level. Q4 underlying EBITDA below Q3 but above Q4'06.

* Underlying EBITDA margin

Q3 2007 Investor Conference Call • Werner Wenning • Page 10



Science For A Better Life



Investor Conference Call

Q3 2007 Results